(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Quarter results tomorrow
(bmo 2024-05-06)
Expected move: +/- 18.72%
Live Chart Being Loaded With Signals
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States...
Stats | |
---|---|
今日成交量 | 26 554.00 |
平均成交量 | 122 806 |
市值 | 10.27M |
EPS | $0 ( 2024-03-29 ) |
下一个收益日期 | ( $0 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.480 |
ATR14 | $0.0110 (1.15%) |
音量 相关性
Bionomics Limited 相关性 - 货币/商品
Bionomics Limited 财务报表
Annual | 2023 |
营收: | $432 666 |
毛利润: | $-12.63M (-2 919.26 %) |
EPS: | $-2.60 |
FY | 2023 |
营收: | $432 666 |
毛利润: | $-12.63M (-2 919.26 %) |
EPS: | $-2.60 |
FY | 2022 |
营收: | $4.18M |
毛利润: | $-6.87M (-164.21 %) |
EPS: | $-2.49 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.50 |
Financial Reports:
No articles found.
Bionomics Limited
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。